Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

• Published in: Science (American Association for the Advancement of Science) Vol. 371; no. 6534; pp. 1152 - 1153
• Main Authors: Muik, Alexander, Wallisch, Ann-Kathrin, Sänger, Bianca, Swanson, Kena A., Mühl, Julia, Chen, Wei, Cai, Hui, Maurus, Daniel, Sarkar, Ritu, Türeci, Özlem, Dormitzer, Philip R., Şahin, Uğur
• Format: Journal Article
• Language: English
• Published: United States The American Association for the Advancement of Science 12.03.2021; American Association for the Advancement of Science
• Subjects: Adult; Aged; Amino acid sequence; Amino acids; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Antisera; China; Coronaviridae; Coronaviruses; COVID-19; COVID-19 - blood; COVID-19 - prevention & control; COVID-19 - virology; COVID-19 vaccines; COVID-19 Vaccines - immunology; Female; Humans; Immunization; Infectivity; Male; Medicine; Microbio; Middle Aged; mRNA; Mutation; Neutralization; Neutralization Tests; Neutralizing; Proteins; Respiratory diseases; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Spike protein; United Kingdom; Vaccines; Young Adult; United Kingdom; China; United Kingdom > UK

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1....